Vivaldi Biosciences, Inc.
Vivaldi Biosciences is focused on developing innovative vaccines using the Delta NS1 platform to protect against epidemic and pandemic viral respiratory diseases, including influenza and COVID-19. Their mission involves creating broad-spectrum, safe, and effective vaccines delivered via nasal spray, leveraging their proprietary Delta NS1 technology to induce strong immune responses.
Industries
Nr. of Employees
small (1-50)
Vivaldi Biosciences, Inc.
New York, New York, United States, North America
Products
Nasal spray universal influenza vaccine (Phase 2 clinical program)
A nasal spray vaccine candidate designed to provide broad protection against diverse influenza strains by using a replication-deficient viral vector that induces interferon and expresses influenza antigens.
Preclinical SARS-CoV-2 + universal influenza combination nasal vaccine
A preclinical intranasal combination vaccine candidate designed to simultaneously target SARS-CoV-2 and influenza using the replication-deficient interferon-inducing viral vector backbone.
Nasal spray universal influenza vaccine (Phase 2 clinical program)
A nasal spray vaccine candidate designed to provide broad protection against diverse influenza strains by using a replication-deficient viral vector that induces interferon and expresses influenza antigens.
Preclinical SARS-CoV-2 + universal influenza combination nasal vaccine
A preclinical intranasal combination vaccine candidate designed to simultaneously target SARS-CoV-2 and influenza using the replication-deficient interferon-inducing viral vector backbone.
Expertise Areas
- Viral vector vaccine development
- Intranasal (mucosal) vaccine delivery
- Interferon-mediated innate immune activation
- Universal influenza vaccine design
Key Technologies
- Replication-deficient attenuated viral vectors
- Intranasal spray delivery
- Interferon-inducing vaccine vectors
- Heterologous antigen expression in viral backbones